Cytocom gets FDA nod for phase 2 trial of Covid drug candidate CYTO-205
Cytocom has secured clearance from the US Food and Drug Administration (FDA) to undertake a phase 2 clinical trial of CYTO-205 for the treatment of Covid-19. The company’s investigational new drug (IND) application for the mid-stage trial has been cleared by the FDA, paving way for Cytocom to assess the safety and efficacy of CYTO-205 […]